

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Health Technology Evaluation

### Equality impact assessment – Scoping

#### **Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines ID6356**

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

A stakeholder at scoping raised concerns that more females had H1-antihistamine-refractory chronic spontaneous urticaria than males. A stakeholder also raised concerns that chronic spontaneous urticaria affects children and young people (particularly those aged 16-18).

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The committee will consider all inequalities presented. It will consider whether its recommendations could have a different impact on people protected by the equality legislation than on the wider population. NICE can only appraise a treatment within its marketing authorisation. Children and young people are beyond the remit of this technology appraisal.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes have been made to the scope.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No additional stakeholders relating to potential equality issues have been identified.

**Approved by Associate Director:** Emily Crowe **Date:** 01/10/2025